Three new FDA warning letters were published yesterday, and they tell a pretty clear story.

Different sites. Different countries. Different types of operations: an OTC manufacturer in Illinois, a sterile drug facility in Germany, and a contract testing lab in India.

But the pattern across all three is the same: FDA rejecting firms’ corrective actions.

Not just citing CGMP violations —explicitly calling out responses that failed to address systemic causes.

Water systems running with failing data for years. Analytical records literally found in garbage bags. Quality units watching problems without forcing action.

The letters are unusually direct in how they dismiss surface-level CAPAs. If you manage a quality system, these are worth studying carefully.